Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Breast

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Disease Sites: Breast

Phase: II

Investigator: Abramson, Vandana

NCTID: NCT03990896

Protocol No: VICCBRE2265

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form